MedTrace Logo

Intratumoral Heterogeneity on [18F]PSMA and [18F]FDG PET/CT in Predicting Invasion and Prognosis of Prostate Cancer

NCT06919159 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 45

Last updated 2025-04-11

No results posted yet for this study

Summary

The purpose of this study is to analyze heterogeneity of prostate cancer（PCa）based on the head-to-head imaging of prostate-specific membrane antigen (PSMA) and fluorodeoxyglucose (FDG) positron emission tomography computed tomography (PET/CT)

Conditions

  • Prostate Cancer (Diagnosis)
  • Prostate-specific Membrane Antigen
  • Positron Emission Tomography (PET)

Interventions

DIAGNOSTIC_TEST

PSMA PET/CT scan

Different developing agents

DIAGNOSTIC_TEST

FDG-PET

Different developing agents

Sponsors & Collaborators

  • Jiequn Yu

    lead OTHER

Principal Investigators

  • Xuena Li, PhD · First Hospital of China Medical University

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-01
Primary Completion
2022-11-20
Completion
2022-11-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06919159 on ClinicalTrials.gov